SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Demythologizing the high costs of pharmaceutical research · Study

ArticleShelves

ArticleDemythologizing the high costs of pharmaceutical research

Donald W. Light2011

Article2011

Demythologizing the high costs of pharmaceutical research

Donald W. Light · Rebecca Warburton

213 citations·0/0 files stored·BioSocieties

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Pharmaceutical Economics and Policy Health Systems, Economic Evaluations, Quality of Life Pharmaceutical industry and healthcare

Abstract

No abstract was published for this record.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 213 citations exist upstream.

References

2003The price of innovation: new estimates of drug development costs 1996Recommendations of the Panel on Cost-Effectiveness in Health and Medicine 1996The Role of Cost-effectiveness Analysis in Health and Medicine 1996The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine 1991Cost of innovation in the pharmaceutical industry 1999Rise and fall of modern medicine 1992Canadian Coordinating Office for Health Technology Assessment.2005Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases

Cited by

2015Why Are Cancer Drugs So Expensive in the United States, and What Are the Solutions?2014High Cancer Drug Prices in the United States: Reasons and Proposed Solutions 2012Innovation and Access to Medicines for Neglected Populations: Could a Treaty Address a Broken Pharmaceutical R&D System?2013Market spiral pricing of cancer drugs 2015Why Is There No Generic Insulin? Historical Origins of a Modern Problem

Related works

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

1999Economic consequences of the progression of rheumatoid arthritis in Swedenarticle · 4 shared references 2000Cost-utility analyses of clinical preventive servicesarticle · 4 shared references 2004Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?article · 3 shared references 2001Decision Making in Health and Medicine: Integrating Evidence and Valuesarticle · 3 shared references 2003Examining the Value and Quality of Health Economic Analyses: Implications of Utilizing the QHESarticle · 3 shared references 2005Systematic review of economic analyses of health care-associated infectionsreview · 3 shared references

Details

Year2011

Typearticle

Published2011-02-07

VenueBioSocieties

ISSN-L1745-8552

Languageen

Citations213

Files0 public / 0

ShelfPharmaceutical Economics and Policy

Identifiers

doi10.1057/biosoc.2010.40

openalex_workW2008771899

Links

Imported from OpenAlex (CC0) — nothing here is generated.

2011

The Cost-Effectiveness of Drug Regulation: The Example of Thorough QT/QTc Studies

2019Is the Patent System a Barrier to Inclusive Prosperity? The Biomedical Perspective